Signal
ProFound Therapeutics Secures $35M Gates Foundation Investment for Preeclampsia Drug Discovery Platform
- Category
- · Funding · Global
- Date
- August 27, 2026
- Source
- OVUM
Summary
Flagship Pioneering's ProFound Therapeutics will utilize its proprietary proteome-mapping platform to identify novel biomarkers and therapeutic targets for preeclampsia and eclampsia. This strategic funding from the Bill & Melinda Gates Foundation aims to address critical gaps in maternal mortality interventions.
The company works in Maternal & Newborn and Diagnostics, and this round ($35M) is new money into that part of the market. Compare it with other recent rounds to see whether prices here are rising or holding steady.
OVUM interpretation layer
The editorial read on this signal — pattern, market-structure implications, and what to watch next.
Sources
- OVUM Primary source
The OVUM Intelligence Brief
Keep reading past this page
The week's funding, launches, and studies in women's health, in plain English.
Weekly. No spam. Unsubscribe anytime.